Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension

Haematologica

Volumn 98, Issue 9, 2013, Pages 1359-1367

  Morris, Claudia R ^a   Kim, Hae Young ^b   Wood, John ^c   Porter, John B ^d   Klings, Elizabeth S ^e   Trachtenberg, Felicia L ^b   Sweeters, Nancy ^f   Olivieri, Nancy F ^g   Kwiatkowski, Janet L ^h   Virzi, Lisa ^b   Singer, Sylvia T ^f   Taher, Ali ⁱ   Neufeld, Ellis J ^j   Thompson, Alexis A ^k   Sachdev, Vandana ^l   Larkin, Sandra ^m   Suh, Jung H ^m   Kuypers, Frans A ^m   Vichinsky, Elliott P ^f  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CHILDREN S HOSPITAL OAKLAND   (United States)

^g TORONTO GENERAL HOSPITAL   (Canada)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k CHILDREN'S MEMORIAL HOSPITAL   (United States)

^l NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^m CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; NITRIC OXIDE; SILDENAFIL;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD FLOW VELOCITY; BLURRED VISION; CLINICAL ARTICLE; DIZZINESS; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EXERCISE; EYE DISEASE; FATIGUE; FEMALE; HEADACHE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW BACK PAIN; LUNG FUNCTION; MALE; MORTALITY; OPEN STUDY; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PHOTOPHOBIA; PILOT STUDY; PULMONARY HYPERTENSION; SCIATICA; SIDE EFFECT; THALASSEMIA; WALKING;

ADULT; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PURINES; RISK FACTORS; SULFONES; THALASSEMIA; VASODILATOR AGENTS;

EID: 84881369321     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.082065     Document Type: Article

References (55)

1. Farmakis D, Aessopos A. Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. Circulation. 2011;123(11):1227-32.
2. Machado RF, Gladwin MT. Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest. 2010;137(6 Suppl):30S-8S.
3. Morris CR, Kim HY, Trachtenberg F, Wood J, Quinn CT, Sweeters N, et al. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood. 2011;118(14):3794-802.
4. Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in beta-thalassemia syndromes: a decade of progress. Am J Med. 2005;118(9):957-67.
5. Du ZD, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major. Am Heart J. 1997;134(3):532-7.
6. Aessopos A, Farmakis D. Pulmonary hypertension in beta-thalassemia. Ann NY Acad Sci. 2005;1054:342-9.
7. Tam DH, Farber HW. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature. Am J Hematol. 2006;81(6):443-7.
8. Hagar RW, Morris CR, Vichinsky EP. Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function. Br J Haematol. 2006;133 (4):433-5.
9. Grisaru D, Rachmilewitz EA, Mosseri M, Gotsman M, Lafair JS, Okon E, et al. Cardiopulmonary assessment in beta-thalassemia major. Chest. 1990;98(5):1138-42.
10. Morris CR, Vichinsky EP. Pulmonary hypertension in thalassemia. Ann NY Acad Sci. 2010;1202:205-13.
11. Phrommintikul A, Sukonthasarn A, Kanjanavanit R, Nawarawong W. Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart. 2006;92(10):1467-72.
12. Atichartakarn V, Likittanasombat K, Chuncharunee S, Chandanamattha P, Worapongpaiboon S, Angchaisuksiri P, et al. Pulmonary arterial hypertension in previously splenectomized patients with betathalassemic disorders. Int J Hematol. 2003;78(2):139-45.
13. Singer ST, Kuypers FA, Styles L, Vichinsky EP, Foote D, Rosenfeld H. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol. 2006;81(9):670-5.
14. Karimi M, Musallam KM, Cappellini MD, Daar S, El-Beshlawy A, Belhoul K, et al. Risk factors for pulmonary hypertension in patients with beta thalassemia intermedia. Eur J Intern Med. 2011;22(6):607-10.
15. Morris CR, Vichinsky E, Singer ST. Pulmonary hypertension in thalassemia: association with hemolysis, arginine metabolism dysregulation and a hypercoaguable state. Adv Pulm Hypertens. 2007;5: 31-8.
16. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127(5): 1523-30.
17. Morris CR. Mechanisms of vasculopathy in sickle cell disease and thalassemia. Hematology Am Soc Hematol Educ Program. 2008;2008:177-85.
18. El-Hady SB, Farahat MH, Atfy M, Elhady MA. Nitric oxide metabolites and arginase I levels in beta-thalassemic patients: an Egyptian study. Ann Hematol. 2012;91(8): 1193-200.
19. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, V S, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294(1):81-90.
20. Morris C, Kuypers F, Kato G, Lavrisha L, Larkin S, Singer T, et al. Hemolysis-associated pulmonary hypertension in thalassemia. An NY Acad Sci. 2005;1054:481-5.
21. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxiainduced pulmonary hypertension. Circulation. 2003;107(25):3230-5.
22. Morris CR, Morris SM Jr, Hagar W, van Warmerdam J, Claster S, Kepka-Lenhart K, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168(1):63-9.
23. Derchi G, Fonti A, Forni GL, Galliera EO, Cappellini MD, Turati F, et al. Pulmonary hypertension in patients with thalassemia major. Am Heart J. 1999;138(2 Pt 1):384.
24. Zakynthinos E, Vassilakopoulos T, Kaltsas P, Malagari E, Daniil Z, Roussos C, et al. Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. Thorax. 2001;56(9):737-9.
25. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol. 2004;73 (5):359-66.
26. Wu KH, Chang JS, Su BH, Peng CT. Tricuspid regurgitation in patients with beta-thalassemia major. Ann Hematol. 2004;83(12):779-83.
27. Aessopos A, Stamatelow G, Skoumas V, Vassilopoulos G, Mantzourani M, Loulopoulos D. Pulmonary hypertension and right heart failure in patients with B-thalassemia intermedia. Chest. 1995;107(1):50-3.
28. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43-54.
29. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105(20):2398-403.
30. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007;110(6):2166-72.
31. Sheth A, Park JE, Ong YE, Ho TB, Madden BP. Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vascul Pharmacol. 2005;42(2):41-5.
32. Derchi G, Forni GL, Formisano F, Cappellini MD, Galanello R, D'Ascola G, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica. 2005;90(4):452-8.
33. Littera R, La Nasa G, Derchi G, Cappellini MD, Chang CY, Contu L. Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood. 2002;100(4):1516-7.
34. Kato GJ. TRV: a physiological biomarker in sickle cell disease. Pediatr Blood Cancer. 2012;58(6):831-2.
35. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15(2):167-84.
36. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004; 350(9):886-95.
37. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011;365(1):44-53.
38. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA. 2012;307(12):1254-6.
39. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57.
40. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011; 4(1):8-17.
41. Lalande S, Snyder EM, Olson TP, Hulsebus ML, Orban M, Somers VK, et al. The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise. Eur J Appl Physiol. 2009;106(4):509-15.
42. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44 (12):2339-48.
43. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011;118(4):855-64.
44. Gladwin MT, Barst RJ, Castro OL, Gordeuk VR, Hillery CA, Kato GJ, et al. Pulmonary hypertension and NO in sickle cell. Blood. 2010;116(5):852-4.
45. Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010;116(5):687-92.
46. Fonseca GH, Souza R, Salemi VC, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterization in sickle cell disease. Eur Respir J. 2012;30(1): 112-8.
47. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16): 2250-94.
48. Dumitrescu D, Oudiz R. Exercise testing and pulmonary hypertension: Six-minute walk testing and cardiopulmonary exercise testing. In: Peacock A, Naeije R, Rubin L, eds. Pulmonary Circulation. London: Hodder Arnold, 2011:138-45.
49. Nebes VL, Morris SM, Jr. Regulation of messenger ribonucleic acid levels for five urea cycle enzymes in cultured rat hepatocytes. Requirements for cyclic adenosine monophosphate, glucocorticoids, and ongoing protein synthesis. Mol Endocrinol. 1988;2(5):444-51.
50. Erdely A, Kepka-Lenhart D, Clark M, Zeidler-Erdely P, Poljakovic M, Calhoun WJ, et al. Inhibition of phosphodiesterase 4 amplifies cytokine-dependent induction of arginase in macrophages. Am J Physiol Lung Cell Mol Physiol. 2006;290(3):L534-9.
51. Tang WHW, Wang Z, Cho L, Brennan DM, Hanzen SL. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol. 2009;53(22):2061-7.
52. Sourij H, Meinitzer A, Pilz S, Grammer TB, Winkelmann BR, Boehm BO, et al. Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography. Atherosclerosis. 2011;218(1):220-5.
53. Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica. 2011;96(11):1605-12.
54. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99 (1):36-43.
55. Morris CR, Gladwin MT. Pulmonary hypertension in sickle cell disease and thalassemia In: Peacock A, Naeije R, Rubin L, eds. Pulmonary Circulation, Third edition. London: Hodder Arnold, 2011:271-87.